As clinical trial complexity, duration, and cost continue to rise, life sciences companies are turning to data to help them ...

In the past week, a Boston biotech led by longtime industry CEO Harvey Berger said it plans to shut down, while another ...

Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...

I can tell you that VDPHL01 has a unique profile unlike current FDA-approved treatments, which are associated with cardiac ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

Good morning, everyone, and welcome to the Anavex Life Sciences Fiscal 2025 First Quarter Conference Call. My name is Clint ...

Sweeping layoffs, funding freezes and executive orders have provoked outcry among federal researchers and their university partners, who fear that science itself is under siege.

In the interconnected ASX healthcare sector it can be common for leaders to be involved in multiple companies and ...

TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics ...

We sat down with Pro Medicus CEO, Dr Sam Hupert on results day to discuss the past six months and the all-important outlook.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...